Deciphera Readies For Next Steps; Brings Third Compound Into Phase I
This article was originally published in The Pink Sheet Daily
Executive Summary
The newly relocated biotech is shifting its focus from science to business development as it moves its third compound into the clinic and begins looking for partners for its other programs.
You may also be interested in...
New Research Highlights Potential And Pitfalls Of BRAF Inhibitors
Surprisingly positive data from two early-stage trials in metastatic melanoma with Plexxikon/Roche’s BRAF inhibitor, PLX-4032, and its quick move into Phase III, is garnering attention for the new class of cancer therapy. But there is one troubling sign of toxicity, and other research on the BRAF pathway is prompting debate over the pros and cons of specific versus broad activity.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.